Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Share-based Compensation (2021 - 2025)

Senti Biosciences has reported Share-based Compensation over the past 5 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $1.4 million for Q4 2025, up 135.54% from a year ago — trailing twelve months through Dec 2025 was $5.7 million (up 225.13% YoY), and the annual figure for FY2025 was $5.7 million, up 225.13%.
  • Share-based Compensation for Q4 2025 was $1.4 million at Senti Biosciences, down from $1.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for SNTI hit a ceiling of $9.2 million in Q2 2022 and a floor of -$2.0 million in Q3 2023.
  • Median Share-based Compensation over the past 5 years was $1.3 million (2024), compared with a mean of $1.8 million.
  • Biggest five-year swings in Share-based Compensation: soared 473.61% in 2022 and later plummeted 187.34% in 2023.
  • Senti Biosciences' Share-based Compensation stood at $735000.0 in 2021, then soared by 473.61% to $4.2 million in 2022, then tumbled by 51.04% to $2.1 million in 2023, then plummeted by 70.69% to $605000.0 in 2024, then soared by 135.54% to $1.4 million in 2025.
  • The last three reported values for Share-based Compensation were $1.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.